Acute Myelogenous Leukemia at Baylor Charles A. Sammons Cancer Center, 2010 to 2012: Retrospective Analysis of Molecular Genetic Evaluation
Over the last several decades, advancements in the understanding of genetic and molecular origins of acute myeloid leukemia (AML) have brought about significant changes in how the disease is classified, diagnosed, and treated. The change from the traditional French-American-British classification sy...
Gespeichert in:
Veröffentlicht in: | Proceedings - Baylor University. Medical Center 2014-10, Vol.27 (4), p.299-304 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 304 |
---|---|
container_issue | 4 |
container_start_page | 299 |
container_title | Proceedings - Baylor University. Medical Center |
container_volume | 27 |
creator | Jones, Catherine Leday, Temekka V. Miller, Alan M. |
description | Over the last several decades, advancements in the understanding of genetic and molecular origins of acute myeloid leukemia (AML) have brought about significant changes in how the disease is classified, diagnosed, and treated. The change from the traditional French-American-British classification system to that of the World Health Organization redefined how the disease is diagnosed not only morphologically but genetically. With genetic information proving to have prognostic value, the newer classification system, which incorporates results of cytogenetic and molecular analyses, allows better definition of disease and risk stratification, ultimately guiding treatment choices. As understanding and advancements in the molecular basis of AML continue to grow and influence patient management, the importance of an accurate and thorough initial patient evaluation is paramount. We performed a review of AML cases diagnosed at Baylor Charles A. Sammons Cancer Center from February 2010 to December 2012 to assess the thoroughness of initial diagnostic evaluations based on current guidelines, including up-to-date molecular analyses for mutations in NPM1, CEBPA, FLT3, and C-KIT. Results showed that patients newly diagnosed with AML undergo thorough diagnostic evaluation in keeping with current recommendations, and many had further genetic and molecular evaluations, which although considered optional or investigational, have prognostic significance. We identified potential areas of improvement for making this diagnostic evaluation more specific to the patient and the patient's disease. Currently, we are investigating having patients undergo reflex genetic testing if they meet certain criteria to better define their specific disease while avoiding unnecessary genetic evaluations that come at increased cost. |
doi_str_mv | 10.1080/08998280.2014.11929140 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmed_primary_25484493</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A384209524</galeid><sourcerecordid>A384209524</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4120-32a1997c0e5780404f04d6bc0486298cdb18338636b83d7a0d72e171ba7821b03</originalsourceid><addsrcrecordid>eNqFkstu1DAUhiMEokPhFSpLbFgwwbckDgukMCoFaSokLmvLcU6mLo49tZNB8wy8NA7TKRQhIS-O5POd-59lZwTnBAv8Cou6FlTgnGLCc0JqWhOOH2QLUtBiyWhBH2aLGVrO1En2JMZrjDlhpHqcndCCC85rtsh-NHoaAV3uwfoNOD9FtIbpGwxGITWit2pvfUCrKxUsRNTk6LMaBu8iWimnIXnAjRBeotQGRqOfLX2NPsEYfNyCHs0OUOOU3UcTke_RpbegJ6sCugAHo9HofKfspEbj3dPsUa9shGe39jT7-u78y-r9cv3x4sOqWS81JxSn4RSp60pjKCqBOeY95l3ZasxFSWuhu5YIxkTJylawrlK4qyiQirSqEpS0mJ1mbw55t1M7QKfTCEFZuQ1mUGEvvTLyvseZK7nxO8lpUQguUoIXtwmCv5kgjnIwUYO1ykHaoCQlq4qK8mJGn_-FXvsppIUkqqrLsuQYl7-pjbIgjet9qqvnpLJhglNcF5QnKv8HlV6XzqW9g96k_3sB5SFAp2vEAP3djATLWUbyKCM5y0geZZQCz_7c0F3YUTcJaA7A3EUY1HcfbCfHX2rpQ5KGiZL9p8hPL6DT5w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1796664006</pqid></control><display><type>article</type><title>Acute Myelogenous Leukemia at Baylor Charles A. Sammons Cancer Center, 2010 to 2012: Retrospective Analysis of Molecular Genetic Evaluation</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Jones, Catherine ; Leday, Temekka V. ; Miller, Alan M.</creator><creatorcontrib>Jones, Catherine ; Leday, Temekka V. ; Miller, Alan M.</creatorcontrib><description>Over the last several decades, advancements in the understanding of genetic and molecular origins of acute myeloid leukemia (AML) have brought about significant changes in how the disease is classified, diagnosed, and treated. The change from the traditional French-American-British classification system to that of the World Health Organization redefined how the disease is diagnosed not only morphologically but genetically. With genetic information proving to have prognostic value, the newer classification system, which incorporates results of cytogenetic and molecular analyses, allows better definition of disease and risk stratification, ultimately guiding treatment choices. As understanding and advancements in the molecular basis of AML continue to grow and influence patient management, the importance of an accurate and thorough initial patient evaluation is paramount. We performed a review of AML cases diagnosed at Baylor Charles A. Sammons Cancer Center from February 2010 to December 2012 to assess the thoroughness of initial diagnostic evaluations based on current guidelines, including up-to-date molecular analyses for mutations in NPM1, CEBPA, FLT3, and C-KIT. Results showed that patients newly diagnosed with AML undergo thorough diagnostic evaluation in keeping with current recommendations, and many had further genetic and molecular evaluations, which although considered optional or investigational, have prognostic significance. We identified potential areas of improvement for making this diagnostic evaluation more specific to the patient and the patient's disease. Currently, we are investigating having patients undergo reflex genetic testing if they meet certain criteria to better define their specific disease while avoiding unnecessary genetic evaluations that come at increased cost.</description><identifier>ISSN: 0899-8280</identifier><identifier>EISSN: 1525-3252</identifier><identifier>DOI: 10.1080/08998280.2014.11929140</identifier><identifier>PMID: 25484493</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><subject>Analysis ; Criticism and interpretation ; Drama ; Genetic research ; Original Research</subject><ispartof>Proceedings - Baylor University. Medical Center, 2014-10, Vol.27 (4), p.299-304</ispartof><rights>Copyright © 2014 Baylor University Medical Center 2014</rights><rights>COPYRIGHT 2014 Taylor & Francis Group LLC</rights><rights>Copyright Baylor University Medical Center Oct 2014</rights><rights>Copyright © 2014, Baylor University Medical Center 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4120-32a1997c0e5780404f04d6bc0486298cdb18338636b83d7a0d72e171ba7821b03</citedby><cites>FETCH-LOGICAL-c4120-32a1997c0e5780404f04d6bc0486298cdb18338636b83d7a0d72e171ba7821b03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4255848/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4255848/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25484493$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jones, Catherine</creatorcontrib><creatorcontrib>Leday, Temekka V.</creatorcontrib><creatorcontrib>Miller, Alan M.</creatorcontrib><title>Acute Myelogenous Leukemia at Baylor Charles A. Sammons Cancer Center, 2010 to 2012: Retrospective Analysis of Molecular Genetic Evaluation</title><title>Proceedings - Baylor University. Medical Center</title><addtitle>Proc (Bayl Univ Med Cent)</addtitle><description>Over the last several decades, advancements in the understanding of genetic and molecular origins of acute myeloid leukemia (AML) have brought about significant changes in how the disease is classified, diagnosed, and treated. The change from the traditional French-American-British classification system to that of the World Health Organization redefined how the disease is diagnosed not only morphologically but genetically. With genetic information proving to have prognostic value, the newer classification system, which incorporates results of cytogenetic and molecular analyses, allows better definition of disease and risk stratification, ultimately guiding treatment choices. As understanding and advancements in the molecular basis of AML continue to grow and influence patient management, the importance of an accurate and thorough initial patient evaluation is paramount. We performed a review of AML cases diagnosed at Baylor Charles A. Sammons Cancer Center from February 2010 to December 2012 to assess the thoroughness of initial diagnostic evaluations based on current guidelines, including up-to-date molecular analyses for mutations in NPM1, CEBPA, FLT3, and C-KIT. Results showed that patients newly diagnosed with AML undergo thorough diagnostic evaluation in keeping with current recommendations, and many had further genetic and molecular evaluations, which although considered optional or investigational, have prognostic significance. We identified potential areas of improvement for making this diagnostic evaluation more specific to the patient and the patient's disease. Currently, we are investigating having patients undergo reflex genetic testing if they meet certain criteria to better define their specific disease while avoiding unnecessary genetic evaluations that come at increased cost.</description><subject>Analysis</subject><subject>Criticism and interpretation</subject><subject>Drama</subject><subject>Genetic research</subject><subject>Original Research</subject><issn>0899-8280</issn><issn>1525-3252</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkstu1DAUhiMEokPhFSpLbFgwwbckDgukMCoFaSokLmvLcU6mLo49tZNB8wy8NA7TKRQhIS-O5POd-59lZwTnBAv8Cou6FlTgnGLCc0JqWhOOH2QLUtBiyWhBH2aLGVrO1En2JMZrjDlhpHqcndCCC85rtsh-NHoaAV3uwfoNOD9FtIbpGwxGITWit2pvfUCrKxUsRNTk6LMaBu8iWimnIXnAjRBeotQGRqOfLX2NPsEYfNyCHs0OUOOU3UcTke_RpbegJ6sCugAHo9HofKfspEbj3dPsUa9shGe39jT7-u78y-r9cv3x4sOqWS81JxSn4RSp60pjKCqBOeY95l3ZasxFSWuhu5YIxkTJylawrlK4qyiQirSqEpS0mJ1mbw55t1M7QKfTCEFZuQ1mUGEvvTLyvseZK7nxO8lpUQguUoIXtwmCv5kgjnIwUYO1ykHaoCQlq4qK8mJGn_-FXvsppIUkqqrLsuQYl7-pjbIgjet9qqvnpLJhglNcF5QnKv8HlV6XzqW9g96k_3sB5SFAp2vEAP3djATLWUbyKCM5y0geZZQCz_7c0F3YUTcJaA7A3EUY1HcfbCfHX2rpQ5KGiZL9p8hPL6DT5w</recordid><startdate>20141001</startdate><enddate>20141001</enddate><creator>Jones, Catherine</creator><creator>Leday, Temekka V.</creator><creator>Miller, Alan M.</creator><general>Taylor & Francis</general><general>Taylor & Francis Group LLC</general><general>Taylor & Francis Ltd</general><general>Baylor Health Care System</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20141001</creationdate><title>Acute Myelogenous Leukemia at Baylor Charles A. Sammons Cancer Center, 2010 to 2012: Retrospective Analysis of Molecular Genetic Evaluation</title><author>Jones, Catherine ; Leday, Temekka V. ; Miller, Alan M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4120-32a1997c0e5780404f04d6bc0486298cdb18338636b83d7a0d72e171ba7821b03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Analysis</topic><topic>Criticism and interpretation</topic><topic>Drama</topic><topic>Genetic research</topic><topic>Original Research</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jones, Catherine</creatorcontrib><creatorcontrib>Leday, Temekka V.</creatorcontrib><creatorcontrib>Miller, Alan M.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Proceedings - Baylor University. Medical Center</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jones, Catherine</au><au>Leday, Temekka V.</au><au>Miller, Alan M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Acute Myelogenous Leukemia at Baylor Charles A. Sammons Cancer Center, 2010 to 2012: Retrospective Analysis of Molecular Genetic Evaluation</atitle><jtitle>Proceedings - Baylor University. Medical Center</jtitle><addtitle>Proc (Bayl Univ Med Cent)</addtitle><date>2014-10-01</date><risdate>2014</risdate><volume>27</volume><issue>4</issue><spage>299</spage><epage>304</epage><pages>299-304</pages><issn>0899-8280</issn><eissn>1525-3252</eissn><abstract>Over the last several decades, advancements in the understanding of genetic and molecular origins of acute myeloid leukemia (AML) have brought about significant changes in how the disease is classified, diagnosed, and treated. The change from the traditional French-American-British classification system to that of the World Health Organization redefined how the disease is diagnosed not only morphologically but genetically. With genetic information proving to have prognostic value, the newer classification system, which incorporates results of cytogenetic and molecular analyses, allows better definition of disease and risk stratification, ultimately guiding treatment choices. As understanding and advancements in the molecular basis of AML continue to grow and influence patient management, the importance of an accurate and thorough initial patient evaluation is paramount. We performed a review of AML cases diagnosed at Baylor Charles A. Sammons Cancer Center from February 2010 to December 2012 to assess the thoroughness of initial diagnostic evaluations based on current guidelines, including up-to-date molecular analyses for mutations in NPM1, CEBPA, FLT3, and C-KIT. Results showed that patients newly diagnosed with AML undergo thorough diagnostic evaluation in keeping with current recommendations, and many had further genetic and molecular evaluations, which although considered optional or investigational, have prognostic significance. We identified potential areas of improvement for making this diagnostic evaluation more specific to the patient and the patient's disease. Currently, we are investigating having patients undergo reflex genetic testing if they meet certain criteria to better define their specific disease while avoiding unnecessary genetic evaluations that come at increased cost.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>25484493</pmid><doi>10.1080/08998280.2014.11929140</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0899-8280 |
ispartof | Proceedings - Baylor University. Medical Center, 2014-10, Vol.27 (4), p.299-304 |
issn | 0899-8280 1525-3252 |
language | eng |
recordid | cdi_pubmed_primary_25484493 |
source | EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Analysis Criticism and interpretation Drama Genetic research Original Research |
title | Acute Myelogenous Leukemia at Baylor Charles A. Sammons Cancer Center, 2010 to 2012: Retrospective Analysis of Molecular Genetic Evaluation |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T06%3A05%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Acute%20Myelogenous%20Leukemia%20at%20Baylor%20Charles%20A.%20Sammons%20Cancer%20Center,%202010%20to%202012:%20Retrospective%20Analysis%20of%20Molecular%20Genetic%20Evaluation&rft.jtitle=Proceedings%20-%20Baylor%20University.%20Medical%20Center&rft.au=Jones,%20Catherine&rft.date=2014-10-01&rft.volume=27&rft.issue=4&rft.spage=299&rft.epage=304&rft.pages=299-304&rft.issn=0899-8280&rft.eissn=1525-3252&rft_id=info:doi/10.1080/08998280.2014.11929140&rft_dat=%3Cgale_pubme%3EA384209524%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1796664006&rft_id=info:pmid/25484493&rft_galeid=A384209524&rfr_iscdi=true |